SARASOTA, Fla. and NOVATO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc.Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced that it has dosed the first patient in its KIK-AS (Knockdown of UBE3A-antisense in Kids with Angelman Syndrome) study of GTX-102, an experimental antisense oligonucleotide being evaluated for the treatment of Angelman syndrome (AS).
The Phase 1/2 open-label, multiple-dose, dose-escalating study will enroll 20 patients to evaluate the safety, tolerability, and potential efficacy of GTX-102 in pediatric patients with Angelman syndrome. This is the first investigational study testing an antisense oligonucleotide as a potential therapy to treat AS. Further details can be referenced at: https://clinicaltrials.gov/ct2/show/NCT04259281.
Today is an important milestone with the dosing of the first patient in the KIK-AS study, stated Dr. Scott Stromatt, GeneTxs Chief Medical Officer GTX-102 has the potential to address the underlying deficiency that causes Angelman syndrome and we are excited, grateful and humbled to be leading this scientific quest. We look forward to the results of this study and sharing them with the Angelman community.
The GeneTx team has achieved a tremendous accomplishment rapidly advancing this program into the clinic, and GTX-102 may one day provide patients with Angelman syndrome with the first targeted therapy and a potentially transformative option for this devastating disease, said Camille L. Bedrosian, M.D., Chief Medical Officer of Ultragenyx.
Chicagos Rush University Medical Center is the first clinical site to begin enrolling patients in the KIK-AS study, with additional sites being planned in Boston, Cincinnati, Denver, Los Angeles, New York and Ottawa, Canada.
When I held the syringe with this investigational treatment in my hand to inject it for the first time, I thought about the scientific advances in genomic and molecular medicine to produce potential treatments that bring hope of changing the disease course and ameliorating severity of symptoms in those with Angelman syndrome, said Elizabeth Berry-Kravis, site principal investigator at Rush. This is an exciting time for the field of neurodevelopmental disorders as we embark on a path to understanding the outcomes of treatments directed at correcting the underlying molecular causes of disease.
Pending additional site activation, GeneTx Biotherapeutics expects to report preliminary data from the first cohorts in the study in early 2021.
About Angelman Syndrome
Angelman syndrome is a rare, neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. The maternal-specific inheritance pattern of Angelman syndrome is due to genomic imprinting of UBE3A in neurons of the central nervous system, a naturally occurring phenomenon in which the maternal UBE3A allele is expressed and the paternal UBE3A is not. Silencing of the paternal UBE3A allele is regulated by the UBE3A antisense transcript (UBE3A-AS), the intended target of GTX-102. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. This condition is typically not inherited but instead occurs spontaneously.
Individuals with Angelman syndrome have developmental delay, balance issues, motor impairment, and debilitating seizures. Some individuals with Angelman syndrome are unable to walk and most do not speak. Anxiety and disturbed sleep can be serious challenges in individuals with Angelman syndrome. While individuals with Angelman syndrome have a normal lifespan, they require continuous care and are unable to live independently. Angelman syndrome is not a degenerative disorder, but the loss of the UBE3A protein expression in neurons results in abnormal communications between neurons. Angelman syndrome is often misdiagnosed as autism or cerebral palsy. There are no currently approved therapies for Angelman syndrome; however, several symptoms of this disorder can be reversed in adult animal models of Angelman syndrome suggesting that improvement of symptoms can potentially be achieved at any age.
GTX-102 is an investigational antisense oligonucleotide designed to target and inhibit expressionof UBE3A-AS. Nonclinical studies show that GTX-102 reduces the levels of UBE3A-AS and reactivates expression of the paternal UBE3A allele in neurons of the CNS. Reactivation of paternal UBE3A expression in animal models of Angelman syndrome has been associated with improvements in some of the neurological symptoms associated with the condition. GTX-102 has been granted Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). InAugust 2019, GeneTx and Ultragenyx announced a partnership to develop GTX-102, with Ultragenyx receiving an exclusive option to acquire GeneTx.
About GeneTx Biotherapeutics
GeneTx Biotherapeutics LLC is a startup biotechnology company singularly focused on developing and commercializing a safe and effective antisense therapeutic for the treatment of Angelman syndrome. GeneTx was launched by FAST, a patient advocacy organization and the largest non-governmental funder of Angelman syndrome research. GeneTx licensed the rights to antisense technology intellectual property from The Texas A&M University System in December 2017.
AboutUltragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyxs strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company's website atwww.ultragenyx.com.
Ultragenyx Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx's expectations regarding plans for its clinical programs and clinical studies, future regulatory interactions, and the components and timing of regulatory submissions are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, including our partnership with GeneTx, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of regulatory filings and approvals (including whether such approvals can be obtained), and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of our products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Annual Report filed on Form 10-K with theSecurities and Exchange CommissiononFebruary 14, 2020, and its subsequent periodic reports filed with theSecurities and Exchange Commission.
Ultragenyx Investors & MediaDanielle Keatley415email@example.com
The rest is here:
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 19th, 2020
- Colonizing Mars may require humanity to tweak its DNA - Space.com - May 19th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - Newswise - May 19th, 2020
- 23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus - Motley Fool - May 19th, 2020
- Global Molecular Diagnostics Industry 2019-2029: Genetic Disorders, Cardiovascular Disorders, Infections and Cancer - Yahoo Finance UK - May 19th, 2020
- Prominent Cancer Researcher to Join DRI and Renown Health - GlobeNewswire - May 19th, 2020
- Research Roundup: HIV vaccination, diabetes two-in-one injection, hybrid fish genetics - The Stanford Daily - May 19th, 2020
- Singapore researches discover specific gene linked to Asian Lung Cancer - BSA bureau - May 19th, 2020
- Grant will help scientists break new ground in gene editing - Newswise - May 19th, 2020
- Genomic Medicine Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Ingersoll Rand, Johnson Controls, Daikin, United... - May 19th, 2020
- Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic... - May 19th, 2020
- Coronavirus immunity passports could create a world of 'us and them'. But here's why they make sense - Genetic Literacy Project - May 19th, 2020
- New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily - May 19th, 2020
- Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development - CNBC - May 19th, 2020
- WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times - May 19th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Size, Share, Trends and Forecast 2026 by Major Players and Business Opportunities Caribou... - May 19th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 19th, 2020
- From Competition To Sharing: How Her Childrens Rare Disease Led Sharon Terry To Revolutionize Medical Research - Forbes - May 9th, 2020
- Infection rates may have links to cancer - Medical News Today - May 9th, 2020
- Twin peeks: Stanford inherits twin registry, expanding research options - Stanford Medical Center Report - May 9th, 2020
- Management of Fertility and Hormonal Health in Women at Risk for Hereditary Gynecologic Cancers - Endocrinology Advisor - May 9th, 2020
- Individualized mosaics of microbial strains transfer from the maternal to the infant gut - Newswise - May 9th, 2020
- The Falsehoods of the 'Plandemic' Video - FactCheck.org - May 9th, 2020
- Its in your genes Whether Covid lands you in hospital or not depends on your body - ThePrint - May 9th, 2020
- FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC - The Cancer Letter - May 9th, 2020
- Research into the health of unborn babies receives government funding - UNSW Newsroom - May 9th, 2020
- Genetics and Weight: Is There an Obesity Gene? - LIVESTRONG.COM - May 9th, 2020
- New medical foundation invests in COVID-19 research funding - News - The University of Sydney - May 9th, 2020
- What Do Your Genetics Have to Do With Your Chances of Dying From Coronavirus? - Vanity Fair - May 3rd, 2020
- Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert - May 3rd, 2020
- Sarepta Therapeutics Announces Research Agreement with US Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as... - May 3rd, 2020
- Evanston hospitals expand to antibody testing - The Daily Northwestern - May 3rd, 2020
- Profits and Pride at Stake, the Race for a Vaccine Intensifies - The New York Times - May 3rd, 2020
- Data On Thousands Of Twins Reveals How Genetics Influences Covid-19 Symptoms - IFLScience - May 3rd, 2020
- The pieces of the puzzle of covid-19s origin are coming to light - The Economist - May 3rd, 2020
- LIST: UW awards $2.2 million to groups, scientists fighting the coronavirus in Wisconsin - WMTV - May 3rd, 2020
- World Laughter Day 2020: Why we must remember that laughter is indeed the best medicine - Hindustan Times - May 3rd, 2020
- When COVID-19 Mutates, What Are the Risks? - MedicineNet - May 3rd, 2020
- Facts that China is trying to suppress about origin of COVID-19 - WION - May 3rd, 2020
- COVID-19: What's RNA research got to do with it? - University of Rochester - May 3rd, 2020
- Medical, tech investments pay off in Covid-19 war - The Straits Times - May 3rd, 2020
- Welcome to the kingdom of the sick - Salon - May 3rd, 2020
- Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection - CMAJ - May 3rd, 2020
- XBiotech Identifies Super Bloods for the Development of a True Human COVID-19 Therapy - GlobeNewswire - May 3rd, 2020
- On National DNA Day, scientists are trying to take the colonialism out of genetics - Massive Science - April 26th, 2020
- Turning On the 'Off Switch' in Cancer Cells - Michigan Medicine - April 26th, 2020
- Turkey's top scientific body invests TL 2.3 billion on 16 vaccine projects over 5 years | Daily Sabah - Daily Sabah - April 26th, 2020
- Covid-19 will pass. What about the racism it has illuminated? - STAT - April 26th, 2020
- Infection Rate May Indicate a Future Diagnosis of Cancer - Cancer Network - April 26th, 2020
- Misleading coronavirus information falsely attributed to Johns Hopkins - AFP Factcheck - April 26th, 2020
- He signed up for a coronavirus vaccine trial using a method that's never been used in humans. Here's why. - CNN - April 26th, 2020
- New study could lead to therapeutic interventions to treat cocaine addiction - Newswise - April 26th, 2020
- As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing - Cornell University The Cornell Daily Sun - April 26th, 2020
- Another Step Towards Earlier Detection of Pancreatic Cancer - MedPage Today - April 26th, 2020
- UW president, biochemistry chair and mathematics professor named to American Academy of Arts and Sciences - UW News - April 26th, 2020
- Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked... - April 26th, 2020
- Childhood Psychopathology Linked to Higher Levels of Genetic Vulnerability of Adult Depression - Clinical OMICs News - April 26th, 2020
- Gdask scientist makes crucial headway in understanding killer virus by isolating COVID-19 DNA from infected patient - The First News - April 26th, 2020
- Ethiopia's Ministry of Health Holds Webinar With Diaspora on COVID-19 Response at Tadias Magazine - Tadias Magazine - April 26th, 2020
- Immunity and our DNA: Why women are the stronger sex - The Age - April 26th, 2020
- Nobel laureate Luc Montagnier inaccurately claims that the novel coronavirus is man-made and contains genetic material from HIV - Health Feedback - April 26th, 2020
- Concert Genetics Presents Real-World Data on Utilization of NGS-Based Diagnostic Tests in NCCN 2020 Abstract - news-herald.net - April 2nd, 2020
- What scientists know about COVID-19 -- and what they don't - PBS NewsHour - April 2nd, 2020
- UVA Finds Way to Improve Cancer Outcomes by Examining Patients' Genes - University of Virginia - April 2nd, 2020
- Brown Alpert Medical School Autism Expert on Latest Advances in Research and Testing - GoLocalProv - April 2nd, 2020
- Coronavirus testing is ramping up. Here are the new tests and how they work. - Livescience.com - April 2nd, 2020
- Muscular Dystrophy Association Announces Formation of Strategic Medical Advisory Team of Experts in Neuromuscular Care and Research - PRNewswire - April 2nd, 2020
- Modalis Obtains Access to Foundational CRISPR IP - BioSpace - April 2nd, 2020
- Group behind NYC COVID-19 tent hospital is forcing medical workers to abide by anti-gay statement of faith - Metro Weekly - April 2nd, 2020
- What is coronavirus and Covid-19? An explainer - CNN - April 2nd, 2020
- COVID-19 Vaccine: Here Are Steps It Will Need to Go Through During Development | Medicine - Sci-News.com - April 2nd, 2020
- Coronavirus morning update: SA deaths now 5, but 50 recoveries in CT, and lifesaving lockdown - Health24 - April 2nd, 2020
- Can India be an outlier in the spread of Covid-19? | Opinion - Hindustan Times - April 2nd, 2020
- Genetic Medicine | Department of Medicine - March 31st, 2020
- Institute of Genetic Medicine | Johns Hopkins Medicine - March 31st, 2020
- Biotech innovations to spur next phase of personalized care - ModernHealthcare.com - March 31st, 2020
- What is genomic medicine? An introduction to genetics in ... - March 31st, 2020
- Patients with Severe Forms of Coronavirus Disease Could Offer Clues to Treatment - Howard Hughes Medical Institute - March 31st, 2020
- Battelle and Wexner Medical Center create new diagnostic test for COVID-19 - The Ohio State University News - March 31st, 2020
- 8 strains of the coronavirus are circling the globe. Here's what clues they're giving scientists. - USA TODAY - March 31st, 2020